These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 20970551

  • 1. Late conversion to mammalian target of rapamycin inhibitor/proliferation signal inhibitors in kidney transplant patients: clinical experience in the last 5 years.
    Sola E, Lopez V, Gutierrez C, Cabello M, Burgos D, Molina MG, Hernandez D.
    Transplant Proc; 2010 Oct; 42(8):2859-60. PubMed ID: 20970551
    [Abstract] [Full Text] [Related]

  • 2. Everolimus: a proliferation signal inhibitor with clinical applications in organ transplantation, oncology, and cardiology.
    Gabardi S, Baroletti SA.
    Pharmacotherapy; 2010 Oct; 30(10):1044-56. PubMed ID: 20874042
    [Abstract] [Full Text] [Related]

  • 3. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus.
    Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Gómez Alamillo C, Calvo Romero N, Arias M.
    Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607
    [Abstract] [Full Text] [Related]

  • 4. Everolimus: a new mammalian target of rapamycin inhibitor for the treatment of advanced renal cell carcinoma.
    Grgic T, Mis L, Hammond JM.
    Ann Pharmacother; 2011 Jan; 45(1):78-83. PubMed ID: 21177421
    [Abstract] [Full Text] [Related]

  • 5. Kaposi's sarcoma in renal transplant recipients--the impact of proliferation signal inhibitors.
    Campistol JM, Schena FP.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i17-22. PubMed ID: 17456614
    [Abstract] [Full Text] [Related]

  • 6. Potential role of proliferation signal inhibitors on atherosclerosis in renal transplant patients.
    Andrés V, Castro C, Campistol JM.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii14-7. PubMed ID: 16815851
    [Abstract] [Full Text] [Related]

  • 7. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
    Errasti P, Izquierdo D, Martín P, Errasti M, Slon F, Romero A, Lavilla FJ.
    Transplant Proc; 2010 Oct; 42(8):3053-4. PubMed ID: 20970608
    [Abstract] [Full Text] [Related]

  • 8. Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors.
    Pascual J.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i27-35. PubMed ID: 17456616
    [Abstract] [Full Text] [Related]

  • 9. Recurrent non-melanoma skin cancer: remission of field cancerization after conversion from calcineurin inhibitor- to proliferation signal inhibitor-based immunosuppression in a cardiac transplant recipient.
    Signorell J, Hunziker T, Martinelli M, Koestner SC, Mohacsi PJ.
    Transplant Proc; 2010 Nov; 42(9):3871-5. PubMed ID: 21094874
    [Abstract] [Full Text] [Related]

  • 10. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 11. Timing of conversion to mammalian target of rapamycin inhibitors is crucial in liver transplant recipients with impaired renal function at transplantation.
    Schleicher C, Palmes D, Utech M, Bonrath E, Senninger N, Schmidt H, Wolters H.
    Transplant Proc; 2010 Sep; 42(7):2572-5. PubMed ID: 20832546
    [Abstract] [Full Text] [Related]

  • 12. Use of proliferation signal inhibitors in the management of post-transplant malignancies--clinical guidance.
    Campistol JM, Albanell J, Arns W, Boletis I, Dantal J, de Fijter JW, Mortensen SA, Neumayer HH, Øyen O, Pascual J, Pohanka E, Schena FP, Serón D, Sparacino V, Chapman JR.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i36-41. PubMed ID: 17456617
    [Abstract] [Full Text] [Related]

  • 13. Regression of left ventricular hypertrophy in kidney transplant recipients: the potential role for inhibition of mammalian target of rapamycin.
    Paoletti E, Cannella G.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S41-3. PubMed ID: 21095451
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Use of proliferation signal inhibitors in non-melanoma skin cancer following renal transplantation.
    de Fijter JW.
    Nephrol Dial Transplant; 2007 May; 22 Suppl 1():i23-6. PubMed ID: 17456615
    [Abstract] [Full Text] [Related]

  • 17. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
    Wüthrich RP, Kistler AD, Serra AL.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
    [Abstract] [Full Text] [Related]

  • 18. Clinical insights for cancer outcomes in renal transplant patients.
    Alberú J.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S36-40. PubMed ID: 21095450
    [Abstract] [Full Text] [Related]

  • 19. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
    Hernández D, Martínez D, Gutiérrez E, López V, Gutiérrez C, García P, Cobelo C, Cabello M, Burgos D, Sola E, González-Molina M.
    Nefrologia; 2011 Nov; 31(1):27-34. PubMed ID: 21270910
    [Abstract] [Full Text] [Related]

  • 20. Can immunosuppressive strategies be used to reduce cancer risk in renal transplant patients?
    Geissler EK.
    Transplant Proc; 2010 Nov; 42(9 Suppl):S32-5. PubMed ID: 21095449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.